C3 GLOMERULOPATHY

Clinical trials for C3 GLOMERULOPATHY explained in plain language.

Never miss a new study

Get alerted when new C3 GLOMERULOPATHY trials appear

Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 1 Completed 2

New hope for rare kidney diseases: early access drug available

Disease control APPROVED_FOR_MARKETING

This program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and kidney damage. Participants must have active disease and limited response to other treatments. The …

Matched conditions: C3 GLOMERULOPATHY

Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated May 17, 2026 02:53 UTC

C3 GLOMERULOPATHY

Get alerted when new C3 GLOMERULOPATHY trials appear

New hope for rare kidney diseases: early access drug available